Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Research

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

MDUK ONMC Professor, Angela Russell, awarded the 2021 Harrington UK Rare Disease Scholar Award

The Harrington Discovery Institute (HDI) in the US has announced five winners of its inaugural UK Rare Disease Scholar Award competition, including a key investigator of the MDUK Oxford Neuromusuclar Centre, Professor Angela Russell.

Two MDUK ONMC professors honoured by the Academy of Medical Sciences

The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including two academics from the MDUK Oxford Neuromuscular Centre.

The MDUK Oxford Neuromuscular Centre's First Annual Scientific Meeting

The Centre hosted a very successful first annual scientific meeting on 12 February 2020 at St Anne’s College, Oxford, including all research groups in the Centre as well as a panel of international experts in the field.

A new research centre tackles neuromuscular diseases

General

The launch of the MDUK Oxford Neuromuscular Centre marks an exciting new stage in the partnership between Muscular Dystrophy UK and the University of Oxford, with the goal of delivering new experimental medicines and developing enhanced clinical trial capacity in adult and paediatric neuromuscular diseases.

First steps towards treating myotonic dystrophy type 1

Collaborative research between teams from the Department of Paediatrics and the Institut de Myologie shows how antisense oligonucleotides can penetrate muscles to treat myotonic dystrophy type 1, a rare muscle disease.

NHS England to fund Spinraza drug, treating children with Spinal Muscular Atrophy

Spinraza – the first treatment for the rare condition spinal muscular atrophy (SMA) – is set to be available for NHS use for children and adults with SMA Types 1, 2 and 3.

Bake Sale for MDUK Oxford Town and Gown Support

MDUK Oxford Neuromuscular Centre Researchers Raise Funds for their runners in the MDUK Oxford Town and Gown

World-leading neurologist appointed to Professorship at MDUK Oxford Neuromuscular Centre

Acclaimed clinical researcher, Professor Laurent Servais, has been appointed Professor of Paediatric Neuromuscular Diseases at the MDUK Oxford Neuromuscular Centre.

MDUK-Oxford University partnership

Changing the landscape for clinical trials by developing a major centre in the UK.